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Abstract
OBJECTIVES—Clinical evidence indicates newborn critical congenital heart disease (CCHD) 
screening through pulse oximetry is lifesaving. In 2011, CCHD was added to the US 
Recommended Uniform Screening Panel for newborns. Several states have implemented or are 
considering screening mandates. This study aimed to estimate the cost-effectiveness of routine 
screening among US newborns unsuspected of having CCHD.
METHODS—We developed a cohort model with a time horizon of infancy to estimate the 
inpatient medical costs and health benefits of CCHD screening. Model inputs were derived from 
new estimates of hospital screening costs and inpatient care for infants with late-detected CCHD, 
defined as no diagnosis at the birth hospital. We estimated the number of newborns with CCHD 
detected at birth hospitals and life-years saved with routine screening compared with no screening.
RESULTS—Screening was estimated to incur an additional cost of $6.28 per newborn, with 
incremental costs of $20 862 per newborn with CCHD detected at birth hospitals and $40 385 per 
life-year gained (2011 US dollars). We estimated 1189 more newborns with CCHD would be 
identified at birth hospitals and 20 infant deaths averted annually with screening. Another 1975 
false-positive results not associated with CCHD were estimated to occur, although these results 
had a minimal impact on total estimated costs.
CONCLUSIONS—This study provides the first US cost-effectiveness analysis of CCHD 
screening in the United States could be reasonably cost-effective. We anticipate data from states 
that have recently approved or initiated CCHD screening will become available over the next few 
years to refine these projections.
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Congenital heart defects; neonatal screening; costs and cost analysis
Critical congenital heart disease (CCHD) was added to the US Recommended Uniform 
Screening Panel for newborns in 2011.1 Many states before and since have proposed or 
approved legislation or regulations requiring CCHD screening at birth hospitals.
CCHD is typically diagnosed prenatally or during postnatal clinical examination. However, 
newborns with CCHD might not present with signs or symptoms of their condition at birth 
hospitals. If these newborns leave the birth hospital without a diagnosis, they are at risk for 
cardiovascular collapse or death.2 Population-based data from California from 1998 to 2004 
suggested at least 0.9 infant deaths per 100 000 live births occurred in the United States due 
to missed CCHD (calculated from unpublished data obtained from study authors),3,4 
although authors suggested the number of infants affected by missed CCHD could be much 
greater. That estimate is equivalent to 36 infant deaths annually in the current US birth 
cohort.5 A retrospective analysis of Florida Birth Defects Registry data from 1998 to 2007 
estimated 23% (n = 825 in 3603) of infants with CCHD did not receive a diagnosis during 
their birth hospitalization, of whom 1.8% died before readmission or upon emergency 
hospital readmission.6
Recent studies in the United States and Europe indicate CCHD screening through pulse 
oximetry (a test that measures levels of blood oxygen saturation) can detect CCHD in 
newborns whose condition is otherwise not apparent at the birth hospital.7 At present, there 
is no published economic evaluation of costs and outcomes of newborn CCHD screening in 
the United States.8 This study aimed to estimate the cost-effectiveness of screening all US 
newborns unsuspected of having CCHD.
METHODS
Model
We developed a cohort state transition model using TreeAge Pro 2011 (Williamstown, MA) 
and Excel software based on available estimates from recent US and European studies (Fig 
1). The model assessed the number of additional newborns with CCHD detected at birth 
hospitals, number of lives saved, and number of life-years gained from screening. We did 
not assess quality-adjusted life-years because of a lack of relevant data. We assessed 
inpatient medical costs from the perspective of the US health care sector. The model’s time 
horizon was infancy (<1 year of age); therefore, costs were not discounted. All costs are 
presented as 2011 US dollars. Where necessary, costs were inflated by using annual 
estimates from the US Producer Price Index for Hospitals.9 Estimates of life expectancy for 
the current US birth cohort were discounted at 3%.10 Model inputs included results from 
analyses of hospital screening costs in New Jersey in 201211 and inpatient costs for infants 
with CCHD born in Florida from 1998 to 2007,6 which were undertaken in part to provide 
information for this analysis (Table 1).
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CCHD has been defined as congenital heart defects that require surgery or catheter 
intervention within the first year of life.2 A 2009 article endorsed by the American Heart 
Association and American Academy of Pediatrics identified a subset of CCHD conditions 
that present with hypoxemia among newborns as amenable to detection through screening 
with pulse oximetry at birth hospitals.2 On the basis of available estimates from recent 
studies, clinical case criteria for this analysis included 12 screening-detectable CCHD 
conditions: aortic interruption atresia/hypoplasia, coarctation hypoplasia of the aortic arch, 
dexto-transposition of the great arteries, double-outlet right ventricle, Ebstein anomaly, 
hypoplastic left heart syndrome, pulmonary atresia (intact septum), single ventricle, 
tetralogy of Fallot, total anomalous pulmonary venous connection, tricuspid atresia, and 
truncus arteriosus. Although screening might also detect critical forms of aortic and 
pulmonary stenosis, we did not include those conditions because administrative diagnostic 
codes (International Classification of Diseases, Ninth Revision, Clinical Modification) from 
which we derived clinical information do not distinguish critical forms of those conditions. 
The 7 conditions identified as primary targets for CCHD screening in the United States are 
dexto-transposition of the great arteries, hypoplastic left heart syndrome, pulmonary atresia, 
tetralogy of Fallot, total anomalous pulmonary venous connection, tricuspid atresia, and 
truncus arteriosus, which mostly or always present with hypoxemia in the newborn period.12
Screening Cohort
Our model assessed a scenario in which all newborns unsuspected of having CCHD were 
screened at US birth hospitals. Nonhospital births were excluded, as were newborns 
diagnosed through existing pre- or postnatal procedures (referred to here as timely 
diagnosed) because we assumed they would not be subject to screening. We estimated the 
prevalence of newborns with late-detected CCHD in the current US hospital birth cohort 
(Table 2). We estimated an annual screening cohort of 3 952 138 newborns, of whom 1534 
had CCHD not diagnosed through existing procedures.
Screening Cost
We estimated hospitals’ screening cost was $13.50 per newborn based on a recent study in 
New Jersey, where a legislative mandate for CCHD screening offered an opportunity to 
collect cost information from a random sample of 7 hospitals.11 This cost was based on a 
time and motion study and the US national average hourly wage for registered nurses plus a 
fringe benefit of 33.2%. Based on a national estimate that 6.7% of newborns are admitted to 
special/intensive care nurseries per year13 the estimated screening time per newborn 
reported in that study, regardless of nursery care facility (eg, well-newborn or special/
intensive care), was just over nine minutes. The associated labor and equipment costs per 
newborn screened were $6.68 and $6.82 (including amortization and maintenance of pulse 
oximeters and the cost of sensors), respectively, yielding a total estimate of $13.50 per 
newborn. Only 1 hospital among 7 in the New Jersey evaluation used fully reusable sensors 
to screen well newborns; therefore, the equipment cost estimate in our base case model 
primarily reflects the cost of fully or partially disposable screening sensors, which are more 
expensive than reusable sensors.
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Screening Performance and Diagnostic Follow-up
Given the US recommendation to screen newborns after 24 hours of birth,1 we used 
screening sensitivity (77.5%) and false-positive rate (0.05%) data from recent meta-analysis 
for our model based on the results of 7 screening studies (n = 132 361 newborns) conducted 
≥24 hours of birth (Table 1).7 CCHD detected among those newborns closely approximated 
the clinical conditions considered in this analysis, with the exception that some cases of 
aortic and pulmonary stenosis were detected in the screening performance studies but not 
included in our analysis due to available data.
We assumed that all newborns who screen positive for CCHD undergo a confirmatory 
echocardiography examination and that a proportion of those newborns require 
transportation to another facility for examination and/or follow-up treatment. The 
assumption that all newborns with questionable screening results undergo echocardiography 
may be conservative. It is recommended that newborns with low pulse oximetry readings 
undergo a full physical examination to rule out other causes of hypoxemia before 
undergoing an echocardiography;12 we did not include the costs or outcomes of such testing 
in our model. A recent analysis of the Florida Birth Defects Registry reported that 43% (n = 
1547/3603) of newborns with CCHD were transferred during their birth hospitalization.6 We 
used this estimate to represent the number of newborns requiring transport to another facility 
after possible CCHD detection through screening.
Infants with true positive screening results were assigned the cost of an echocardiography 
with a positive result (eg, a CCHD diagnosis). Infants with false positive screening results 
were assigned the cost of an echocardiography with a negative result (i.e., no CCHD 
diagnosis). Infants with false negative screening results, excluding those that died in the 
community, were assigned the cost of a positive echocardiography (assumed to occur upon 
hospital re-admission). Infants with CCHD in the no screening scenario discharged without 
a diagnosis and subsequently re-admitted were also assigned the cost of a positive 
echocardiography. We used Current Procedural Terminology codes and a national private 
health insurance claims data set, the MarketScan 2009 Commercial Claims and Encounters 
Research Database,14 to estimate the costs of inpatient infant echocardiography (including 
physician interpretation) and emergency ground transport by ambulance to another facility 
(Table 1). We assigned an aggregate hospital cost per day ($4294) to infants ultimately 
diagnosed with CCHD based on information from the online database of the Agency for 
Healthcare Research and Quality Health Care Utilization Project 2009 Kids’ Inpatient 
Database (www.hcupnet.ahrq.gov).15 This estimated cost represents the mean hospital cost 
per day for infant hospitalizations with a principal diagnosis for CCHD conditions 
considered in this analysis. We assumed infants who did not receive a CCHD diagnosis at 
the birth hospital would be readmitted to a facility capable of treating CCHD and would not 
require transfer to another hospital.
Hospitalizations and Mortality
We used available estimates from the published literature to make inferences about the 
likely experiences of infants detected through routine CCHD screening (Table 1). On the 
basis of the Florida Birth Defects Registry study, infants with late-detected CCHD (defined 
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as diagnosis after birth hospital discharge) spent an average of 18% more days in inpatient 
care compared with infants with timely detected CCHD during the first year of life (44.3 vs 
37.5 days). This estimate was adjusted for sociodemographic (eg, race/ethnicity) and clinical 
factors (eg, CCHD type). We assumed that infants that died during the first year of life 
would experience half the number of hospitalized days surviving infants did. As noted 
earlier, an analysis of the Florida Birth Defects Registry reported 1.8% of deaths among 
infants with late-detected CCHD occurred either outside a hospital following birth hospital 
discharge or upon emergent hospital readmission after birth hospital discharge.6 We 
assumed CCHD detection through screening would eliminate such deaths but not affect 
other deaths among infants with CCHD.
Sensitivity Analyses
A dearth of previous research on this topic limited our options for sensitivity analysis of the 
model’s base case assumptions. For this reason, we varied base case estimates by 50% in 
both directions for most model inputs. In addition, we examined 2 alternate scenarios. In 
one, we assumed hospitals exclusively used reusable screening sensors for well newborns at 
a cost of $7.74 per newborn (inclusive of labor and equipment), based on the recent New 
Jersey study of hospital screening costs.11 This value already fell within the range of our 
primary sensitivity analysis, although we included this separate test to directly investigate 
the potential cost impact of reusable screening sensors. In the second alternate analysis, we 
tested a scenario in which all deaths among infants with late-detected CCHD were avoided 
as a result of timely detection. Such a mortality improvement is not likely, but this scenario 
seemed worth testing given the data challenges that hinder robust estimates of avoidable 
mortality among infants with late-detected CCHD.
We first assessed model inputs in isolation through 1-way sensitivity analyses. We then used 
a probabilistic sensitivity analysis of 1000 simulations in which all model inputs were 
simultaneously varied within their specified range using triangular probability distributions. 
We examined probability estimates that screening would be cost-effective at monetary 




In a hypothetical scenario of routine CCHD screening for US newborns unsuspected of 
having CCHD, we estimated 1189 more newborns with CCHD would be identified at birth 
hospitals annually, 20 infant deaths would be averted, and 614 life-years would be gained 
(Table 3). We estimated 345 newborns with CCHD would still be discharged from birth 
hospitals annually without CCHD detection (because screening is not 100% sensitive to 
detect CCHD), and routine screening would yield 1975 false-positive results.
Without routine screening, the total estimated inpatient cost for CCHD during all of infancy 
averaged over the entire cohort was $70.32 per infant (Table 3). With screening, the total 
estimated average cost for inpatient care, plus screening and associated costs, was $76.59 
Peterson et al. Page 5













per infant; hence, an incremental cost of $6.28 per newborn screened. This additional cost 
consists of screening and confirmatory testing, slightly offset by anticipated savings in 
inpatient costs during infancy. The estimated cost of false-positive screening results 
(confirmatory echocardiography and transportation when necessary) constituted a modest 
3% ($0.20 per infant screened) of the estimated incremental screening cost per newborn 
(data not shown).
We estimated an incremental cost of $20 862 per additional newborn with CCHD detected 
at birth hospitals and $40 385 per life-year gained (Table 3). Taking into account only the 
additional cost of screening (without respect to any reduction in hospital treatment costs 
during infancy as a result of timely detection) the estimated cost per additional newborn 
with CCHD detected at the birth hospital was $45 724 (data not shown).
Sensitivity Analyses
We tested the influence of each model input in isolation through a series of 1-way sensitivity 
analyses (Table 4). On the basis of the primary sensitivity analysis range of ±50%, we 
specified that for each model input (Table 1), the parameters that had the greatest relative 
influence on the results were as follows: the number of hospitalized days for infants with 
late-detected CCHD surviving infancy (range for the incremental cost per life-year gained: −
$134 614 [cost-saving] to $215 383), the proportion of late detected CCHD among infants 
with CCHD (range: $11 004 to $108 528), and the hospital cost to screen each newborn 
(range: −$3052 [cost-saving] to $83 821). The parameters that had the least relative 
influence on the model results were the cost of echocardiography, cost and probability of 
transport for echocardiography and/or treatment, the mortality rate among infants with 
screening-detected CCHD, and the false-positive rate.
The alternate 1-way sensitivity analyses indicated reusable sensors and greater mortality 
improvements could have a substantial impact on the model results. If all hospitals used 
fully reusable sensors to screen well newborns, we estimated screening would incur just an 
additional $0.52 per newborn and $3319 per life-year gained (Table 4). If all deaths among 
infants with late-detected CCHD were avoided by virtue of screening detection, our model 
estimated 94 lives would be saved annually (data not shown), at an incremental cost per life-
year gained of $10 817 (Table 4).
The probabilistic sensitivity analysis indicated a 33% chance the incremental cost of 
screening for CCHD compared with existing clinical practice would be cost-saving; that is, 
the net cost would be negative. The analysis indicated a 52% chance the incremental cost of 
screening would be <$50 000 per life-year gained and a 73% chance the incremental cost of 
screening would be <$100 000 per life-year gained (Fig 2).
DISCUSSION
We estimated routine screening of US newborns would identify an additional 1189 infants 
with CCHD at birth hospitals that would otherwise be discharged without a diagnosis. We 
estimated screening would save 20 infant lives annually at a cost of $40 385 per life-year 
gained under base case assumptions. Sensitivity analyses suggested screening is likely to be 
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cost-effective under a range of plausible circumstances. Notably, screening was estimated to 
incur an additional cost of approximately just $0.50 per newborn if all hospitals used 
reusable sensors to screen well-newborns, which is a conceivable scenario. The average 
private insurance reimbursement for inpatient infant echocardiography in our analysis was 
approximately $200, which is low relative to hospital charges. That cost had little influence 
on the total estimated cost of screening due to the small number of infants referred for 
echocardiography. A sensitivity analysis tested the echocardiography cost at approximately 
$1000 for each infant. That analysis indicated the total cost per newborn screened would 
increase by less than $0.40 per newborn compared to the base case analysis (from $6.28 to 
$6.66) and the cost-effectiveness ratio per life year gained would rise only modestly (from 
$40 385 to $42 874).
A recently published UK study assessed the cost-effectiveness of adding CCHD screening 
through pulse oximetry to standard newborn clinical examinations.17 UK researchers 
estimated an additional 30 cases of clinically significant CCHD would be detected through 
screening per 100 000 live births, at an incremental cost per case detected of ~£24 000 in 
2009 currency, equivalent to $37 400 (stats.oecd.org; £1 = $1.52 during 2009). This is 
somewhat lower than our finding of an additional $45 724 (2011 value) cost per CCHD case 
detected before accounting for reduced hospital costs attributable to timely diagnoses. 
However, the UK study used a different definition of CCHD than we used here, our study 
was based on a different clinical setting, and UK health care costs are generally lower than 
US costs.
A strength of the present analysis is its explicit calculation of an incremental cost per life-
year gained. No previous cost studies have provided such estimates.2,17,18 Another strength 
was that we initiated original analyses to generate empirical estimates of hospital costs and 
outcomes using representative data from individual US states. The estimates of screening 
costs were derived from an analysis of observed screening practices in a representative 
sample of birthing hospitals in New Jersey.11 The estimates of costs attributable to 
preventable hospitalized days and preventable deaths were derived from an analysis of the 
statewide, population-based Florida Birth Defects Registry and that state’s hospitalization 
data.6,19–21 Estimates of screening performance were taken from a recent systematic review 
and meta-analysis.7
Our study had a number of limitations. Hospitals in other states might implement CCHD 
screening differently than New Jersey does and do so at a different average cost. However, 
given the widespread use of disposable screening sensors in most NJ hospitals, screening 
costs may be lower in other states if reusable sensors are widely adopted. Recent CCHD 
screening time estimates have been as little as 3.5 minutes per newborn.19 However, our 
screening time estimate of nine minutes per newborn was based on a random sample of 
screenings observed by researchers and is consistent with a similar recent observational 
study that estimated 10 minutes per newborn.20 The assumption in the New Jersey study that 
the cost of nursing time for CCHD screening is approximated by the value of average hourly 
compensation, although standard in economic evaluations, may be questioned by some 
observers. If nurses are able to fit this activity in their daily work schedule, as was the case 
in the New Jersey hospital sample, hospital personnel budgets may not increase if routine 
Peterson et al. Page 7













screening is undertaken. However, this study did not account for start-up costs related to a 
new screening program, such as nurse training.
Florida has the fourth highest number of annual live births in the United States,10 although 
experiences with CCHD among infants in that state may not be nationally representative. 
The Florida study was based on data from the state’s birth defects registry, which identifies 
infants with CCHD based on International Classification of Diseases, Ninth Revision, 
Clinical Modification codes from primarily hospital discharge data but does not include 
clinically verified diagnoses.21–24 The Florida Birth Defects Registry is reported to miss up 
to 15% of birth defects, depending on the defect.24
We used an overall estimate of 1.8% avoidable mortality among infants with late-detected 
CCHD based on an analysis of Florida infants,6 which is equivalent to 28 avoidable deaths 
among the 1534 infants we estimated have late-detected CCHD in the current US birth 
cohort. This overall estimate, which does not take into account the fact that mortality among 
such infants is likely to vary substantially by CCHD type, may be conservative. As 
previously cited, a California study estimated a minimum of 36 deaths due to missed CCHD 
in the current birth cohort.3 A study in Wisconsin from 2002 through 2006 assessed 
nonhospital and emergency department deaths within 2 weeks of birth among infants with 
all types of heart disease and reported a higher death rate, the equivalent of 103 deaths in the 
current US birth cohort.25 However, that study did not report the total number of infants in 
the cohort with CCHD as required for our model.
Future analyses should go beyond our cost approach to include differences in noninpatient 
health care costs during and beyond infancy. Comparative data on health care resource 
utilization among children with CCHD who received timely diagnoses during their newborn 
period could facilitate a future cost-effectiveness analysis of CCHD screening with a longer 
time horizon. Such data could also provide additional estimates to refine the sensitivity 
analysis we presented in this preliminary economic evaluation of routine newborn CCHD 
screening. A future detailed analysis of mortality among infants with late-detected CCHD 
could also provide information to further refine model assumptions regarding deaths 
potentially avoidable through CCHD screening. Our analysis assumed full life expectancy 
for infants with CCHD who do not die due to late detection of their condition, although life 
expectancy varies substantially by CCHD type. An additional model extension could include 
the costs and health benefits of detecting non-CCHD conditions through CCHD screening. 
A prospective screening study from Sweden noted 45% of newborns with false-positive 
results from CCHD screening (ie, newborns with low pulse oximetry readings who did not 
ultimately receive CCHD diagnoses) had another significant heart malformation, lung 
problem, or infection.18 Detecting such conditions through CCHD screening may have 
added health benefits, which could conceivably lower the overall incremental cost estimates 
reported here. Incorporating the costs and benefits of detecting non-CCHD conditions in a 
future cost-effectiveness analysis would, however, require robust, data on the outcomes of 
such conditions in the absence of CCHD screening.
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Clinical evidence indicates newborn CCHD screening is a lifesaving program. Based on 
inputs from recent studies, CCHD screening appears cost-effective using conventional 
thresholds and may be cost-saving under some circumstances. We anticipate data from US 
states that have recently approved or initiated routine CCHD screening will become 
available over the next few years to refine these projections.
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WHAT’S KNOWN ON THIS SUBJECT
Critical congenital heart disease (CCHD) was recently added to the US Recommended 
Uniform Screening Panel for newborns.
WHAT THIS STUDY ADDS
Routine screening could cost an estimated additional $6.28 per newborn and $40 385 per 
life-year gained. The incremental cost of screening might be approximately $0.50 per 
newborn with reusable sensors. Future analysis of newborn screening programs may help 
refine these projections.
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Cohort state transition model of routine screening for CCHD in the United States.
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Probabilistic sensitivity analysis of cost per life-year gained.
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TABLE 1
Model Inputs for Routine Newborn Screening for CCHD in the United States
Parameter Base Case Source SAa/Alternate 1-way SA
Costsb
 Cost per newborn screened for CCHD through pulse 
oximetry
$13.50 Peterson et al11 ±50%/$7.74c
 Cost of echocardiography (positive result; CCHD 
diagnosis)
$236 MarketScan,d CPT code: 
93303+93320+93325
$83, $1084
 Cost of echocardiography (negative result; no CCHD 
diagnosis)
$206 MarketScan,d CPT code: 93306 $65, $976
 Cost of ambulance transport for offsite 
echocardiography or treatment
$439 MarketScan,d CPT code: 99466 $16, $1582
 Cost of daily hospital treatment of infants with CCHD $4294 Healthcare Cost Utilization Project 
Kids’ Inpatient Databasee
±50%
Hospitalized days during infancy
 Screening-detected CCHD: survive infancy 37.5 Peterson et al6 ±50%
 Screening-detected CCHD: death during infancy 18.8 Assumption: 50% of days for infants 
who survive
±50%
 Late-detectedf CCHD: survive infancyg 44.3 Peterson et al6 ±50%
 Late-detected CCHD: death during infancy 22.1 Assumption: 50% of days for infants 
who survive
±50%
 Late-detected CCHD: death upon emergent hospital 
readmission
3.0 Peterson et al6
Transition probabilities
 Late-detected CCHD 0.2290 Peterson et al6 ±50%
 Newborn transported to another hospital for 
echocardiography or treatment
0.4290 ±50%
 Death during infancy if CCHD is screening detectedh 0.0618 ±50%
 Death if CCHD is late detected:
  Nonhospital death after birth hospital discharge 0.0085 ±50%
  Death upon emergent hospital readmission after birth 
discharge
0.0097 ±50%
  Other death during infancy 0.0618 ±50%/0
  Pulse oximetry test performance:
   Sensitivity 0.7750 Thangaratinam (2012)5 0.60, 1.00i
   False-positive rate 0.0005 0, 0.002i
Health outcomes




The probabilistic SA used triangular distributions for all inputs.
b
All costs presented as 2011 US dollars.9
c
Assumed hospitals exclusively used reusable sensors for well newborns.
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d
MarketScan 2009 Commercial Database query: private insurance, fee for service (capitated plans excluded), inpatient services for patients’ age <1 
y. Model inputs are mean payments for Current Procedural Terminology codes after eliminating high and low outliers (top and bottom 1%). 
Sensitivity analysis used minimum and maximum values.
e
2009 Agency for Healthcare Research and Quality Healthcare Cost Utilization Project Kids’ Inpatient Database database query: mean hospital 
cost per day among infants with CCHD (by International Classification of Diseases, Ninth Revision, Clinical Modification code: aortic 
interruption/atresia/hypoplasia: 747.11, 747.22); coarctation/hypoplasia of the aortic arch: 747.10; d-transposition of the great arteries: 745.10; 
double-outlet right ventricle: 745.11; Ebstein anomaly: 746.2; hypoplastic left heart syndrome: 746.7; pulmonary atresia: 746.01; single ventricle: 
745.3; teratology of Fallot: 745.2; total anomalous pulmonary venous connection: 747.41; single ventricle: tricuspid atresia: 746.1; truncus 
arteriosus: 745.0) as the principal diagnosis (includes newborn costs).
f
Late detected = no CCHD diagnosis before birth hospital discharge (refers to no screening scenario and infants with false-negative results in 
screening scenario).
g
Twenty percent more days than infants with screening-detected CCHD, estimate inferred from the source study.
h
Mortality estimate based death among infants with late detected CCHD who died after a postbirth hospital admission in the source study.
i
Sensitivity analyses values are maximum and minimum values from screening studies performed ≥24 h.
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TABLE 2
Estimated US Screening Cohort






US Live births, in-hospital 3 957 304 98.9% of 4 000 279 live births US Vital Statistics Reports (2011; 
based on 2010 data for total live 
births),4 US National Center on 
Health Statistics (2011; based on 
2009 data for proportion of hospital-
based births)7
Condition prevalence
 CCHD screening targetsa 169.3 6700 Based on a population studyb Peterson et al6
  Timely detected CCHDc 130.5 5165
  Late-detected CCHD 38.8 1534




Aortic interruption/atresia/hypoplasia, coarctation/hypoplasia of the aortic arch, dexto-transposition of the great arteries, double-outlet right 
ventricle, Ebstein anomaly, hypoplastic left heart syndrome, pulmonary atresia (intact septum), single ventricle, tetralogy of Fallot, total anomalous 
pulmonary venous connection, tricuspid atresia, and truncus arteriosus.
b
Refers to late CCHD detection of 825 of 3603 (22.9%) infants live-born from 1997 to 2008, matched to hospital discharge records and with 1 of 
the CCHD conditions assessed in this analysis among a Florida hospital-based, live-birth cohort of 2 128 236 for that period.25
c
Timely detection defined in source study as CCHD diagnosis before birth hospital discharge.
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TABLE 3
Base Case Results for CCHD Screening in the United States






 True positives (additional cases identified at birth hospitals) 0.000301 1189 —
 False-positives 0.000500 1975 —
 False-negatives 0.000087 345 —
Screening health benefits —
 Lives saved 0.000005 20 —
 Life-years gained 0.000155 614 —
Screening cost —
 Average costs per newborn: —
  No screening $70.32 —
   Confirmatory echocardiography (% of total cost) $ 0.09 (<1%)
   Hospitalizations during infancy (% total cost) $ 70.23 (99%) —
  Screening $76.59 —
   Screening (% of total cost) $13.50 (18%) —
   Confirmatory echocardiography (% total cost) $ 0.19 (<1%) —
   Transportation to echocardiography or treatment (% of 
total cost)
$ 0.15 (<1%) —
   Hospitalizations during infancy (% total cost) $62.72 (82%) —
  Total additional cost of screening compared with 
existing practice
$6.28 $24 802 782 —
Screening cost-effectiveness
  Per case identified — — $20 862
  Per life-year gained — — $40 385
a
Estimated annual cohort of hospital-born newborns unsuspected of having CCHD: 3 952 138 (see Table 2 for details).
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TABLE 4
One-way Sensitivity Analyses
Parameter Model Input Incremental Cost of 
Screening per 
Newborn




 Screening High: $20.25 +$13.03 $83 821
Low: $6.75 −$0.47 −$3052a
Alternate: $7.74 +$0.52 $3319
 Echocardiography (positive result [ie, CCHD diagnosis]/
negative result)
High: $1084/$976 +$6.66 $42 874
Low: $83/$65 +$6.20 $39 928
 Transport for echocardiography High: $1852 +$6.67 $42 909
Low: $16 +$6.13 $39 448
 Daily cost of hospital treatment High: $6442 +$2.55 $16 436
Low: $2147 +$10.00 $64 333
Hospitalized days during infancy
 Infants with screening detected CCHD: survive infancy High: 56.3 +$2.55 $16 436
Low: 18.8 +$10.00 $64 33
 Infants with screening detected CCHD: death during 
infancy
High: 28.1 +$7.02 $45 202
Low: 9.4 +$5.53 $35 567
 Infants with late-detectedb CCHD: survive infancy High: 66.4 −$20.92 −$134 614a
Low: 22.1 +$33.47 $215 383
 Infants with late-detected CCHD: death during infancy High:33.2 +$5.41 $34 803
Low: 11.1 +$7.14 $45 966
Transition probabilities
 Late detected CCHD High: 0.3435 +$2.56 $11 004
Low: 0.1145 +$9.99 $108 528
 Transport for echocardiogram or treatment High: 0.6435 +$6.35 $40 870
Low: 0.2145 +$6.20 $39 899
 Mortality among infants with late-detected CCHD
  Nonhospital death after birth hospital discharge High: 0.1272 +$6.51 $33 972
Low: 0.0042 +$6.04 $50 701
  Death upon emergent hospital admission High: 0.0145 +$6.53 $33 156
Low: 0.0048 +$6.02 $52 870
  Other death during infancy (also the mortality rate 
among infants with screening-detected CCHD in the model)
High: 0.0937 +$6.39 $42 550
Low: 0.0309 +$6.16 $38 357
+$7.77 $10 817
Alternate: 0 for infants with 
screening-detected CCHD
Pulse oximetry test performance: sensitivity High: 1.00 +$4.12 $20 553
Low: 0.60 +$7.95 $66 093
Pulse oximetry test performance: false-positive rate High: 0.002 +$6.87 $44 195
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Parameter Model Input Incremental Cost of 
Screening per 
Newborn
Incremental Cost per 
Life-Year Gained 
From Screening




Late detected is no CCHD diagnosis before birth hospital discharge (refers to no screening scenario and infants with false-negative results in 
screening scenario).
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